Insider Buying: Keros Therapeutics (NASDAQ:KROS) Director Acquires $10,190.00 in Stock

Keros Therapeutics, Inc. (NASDAQ:KROS) Director Jean Jacques Bienaime bought 1,000 shares of the firm’s stock in a transaction dated Monday, June 15th. The shares were acquired at an average price of $10.19 per share, for a total transaction of $10,190.00. Following the acquisition, the director directly owned 17,592 shares of the company’s stock, valued at approximately $179,262.48. The trade was a 6.03% increase in their position. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jean Jacques Bienaime also recently made the following trade(s):

• On Wednesday, April 15th, Jean Jacques Bienaime purchased 1,000 shares of Keros Therapeutics stock. The shares were bought at an average price of $11.70 per share, for a total transaction of $11,700.00.

Keros Therapeutics Price Performance

KROS stock opened at $10.69 on Friday. The company has a 50 day moving average price of $11.06 and a 200 day moving average price of $14.67. Keros Therapeutics, Inc. has a fifty-two week low of $9.69 and a fifty-two week high of $22.55. The stock has a market capitalization of $211.46 million, a PE ratio of -3.55 and a beta of 0.94.

Keros Therapeutics (NASDAQ:KROS) last announced its quarterly earnings data on Thursday, May 14th. The company reported ($1.21) EPS for the quarter, missing analysts’ consensus estimates of ($1.02) by ($0.19). Keros Therapeutics had a negative net margin of 256.60% and a negative return on equity of 17.04%. The firm had revenue of $0.37 million during the quarter, compared to the consensus estimate of $1.93 million. As a group, equities analysts expect that Keros Therapeutics, Inc. will post -5.19 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on KROS. Wells Fargo & Company cut their target price on shares of Keros Therapeutics from $23.00 to $20.00 and set an “overweight” rating on the stock in a research report on Thursday, March 5th. Wall Street Zen cut shares of Keros Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, May 16th. Finally, Weiss Ratings cut shares of Keros Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research report on Friday, May 15th. Three equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $20.40.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Western Standard LLC increased its holdings in shares of Keros Therapeutics by 42.7% in the third quarter. Western Standard LLC now owns 2,189,882 shares of the company’s stock worth $34,644,000 after acquiring an additional 654,989 shares in the last quarter. Renaissance Technologies LLC increased its stake in Keros Therapeutics by 282.5% during the 4th quarter. Renaissance Technologies LLC now owns 591,686 shares of the company’s stock worth $12,047,000 after purchasing an additional 436,986 shares in the last quarter. Canada Pension Plan Investment Board acquired a new stake in Keros Therapeutics during the 2nd quarter worth approximately $4,251,000. Caption Management LLC raised its holdings in Keros Therapeutics by 114.1% during the 2nd quarter. Caption Management LLC now owns 36,078 shares of the company’s stock worth $482,000 after buying an additional 291,997 shares during the period. Finally, Qube Research & Technologies Ltd lifted its stake in Keros Therapeutics by 683.7% in the third quarter. Qube Research & Technologies Ltd now owns 303,122 shares of the company’s stock valued at $4,795,000 after buying an additional 264,445 shares in the last quarter. 71.56% of the stock is currently owned by institutional investors.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-?) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.